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The combined cytoactive eﬀects of American ginseng (Panax quinquefolius) and licorice (Glycyrrhiza uralensis)r o o te x t r a c t s
were investigated in a hepatocarcinoma cell line (Hep-G2). An isobolographic analysis was utilized to express the possibility
of synergistic, additive or antagonistic interaction between the two extracts. Both ginseng and licorice roots are widely utilized
in traditional Chinese medicine preparations to treat a variety of ailments. However, the eﬀect of the herbs in combination is
currently unknown in cultured Hep-G2 cells. Ginseng (GE) and licorice (LE) extracts were both able to reduce cell viability. The
LC50 values, after 72h, were found to be 0.64 ± 0.02mg/mL (GE) and 0.53 ± 0.02mg/mL (LE). An isobologram was plotted,
which included ﬁve theoretical LC50s calculated, based on the ﬁxed fraction method of combination ginseng to licorice extracts
to establish a line of additivity. All combinations of GE to LE (1/5, 1/3, 1/2, 2/3, 4/5) produced an eﬀect on Hep-G2 cell viability
but they were all found to be antagonistic. The LC50 of fractions 1/3, 1/2, 2/3 were 23%, 21% and 18% above the theoretical LC50.
Lactate dehydrogenase release indicated that as the proportion of GE to LE increased beyond 50%, the inﬂuence on membrane
permeability increased. Cell-cycle analysis showed a slight but signiﬁcant arrest at the G1 phase of cell cycle for LE. Both GE and
LE reduced Hep-G2 viability independently; however, the combinations of both extracts were found to have an antagonistic eﬀect
on cell viability and increased cultured Hep-G2 survival.
1.Introduction
American ginseng (Panax quinquefolius) and Asian licorice
(Glycyrrhiza uralensis) roots have a long history of use in
traditional Chinese medicine (TCM). These roots are often
used in combination with other herbal ingredients with the
goal of improving the eﬀectiveness of the TCM preparations.
Ginseng and licorice roots are likely the most utilized TCM
ingredients [1], and both roots are also now utilized by
the nutraceutical and functional food industries for their
purported bioactive and functional properties [2–4].
The main bioactive ingredients found in ginseng are
thought to be a group of dammarane triterpene saponins,
which are also known as ginsenosides [5], and one of
the main active ingredient in licorice is glycyrrhizic acid,
which is an oleanane triterpene saponin. Both roots also
contain a variety of other phytochemical compounds such
as polysaccharides and polyphenols [4, 6] that may add
additional beneﬁts to tinctures or decoctions.
Licorice root extracts and glycyrrhizic acid have been
reported to have both cytotoxic and hepato-protective
properties. Glycyrrhizic acid extracted from licorice root
was reported to protect against aﬂatoxin B1 injury in Hep-
G2 cells [7] and reduced free fatty acid-induced hepatic
lipotoxicity in both cultured Hep-G2 cells and high-fat-
diet-induced lipotoxicity in rats [8]. Furthermore, licorice
and glycyrrhizic acid protected primary hepatocytes against
azathioprine (1μM) injury, an immune suppressant drug
that has hepatic side eﬀects [9]. Glycyrrhizic acid has also
been clinically used in Japan to treat chronic hepatitis [10].
Licorice extracts have exhibited anti-inﬂammatory activity
and inhibited cultured hepatic carcinoma cell (Hep-3B)
proliferation [3]. A licorice extract also reduced prostate
speciﬁc antigen release,and reduced culturedprostate cancer
cell line (LNCaP) proliferation [11] and is one of seven
ingredients in the herbal supplement PC-SPES [12].
Ginseng root and ginsenosides have been associated with
a wide range of biological activities such as anti-diabetic2 Evidence-Based Complementary and Alternative Medicine
[13, 14], immune stimulation [15, 16] and an ability to
inhibit the growth of variety of cultured cancer cells [5,
17, 18]. The precise mechanism attributed to ginseng and
ginsenoside cellular cytotoxicity is not entirely clear but an
interaction with the cell membranes leading to membrane
permeation has been previously reported [18].
The objective of this study was to determine if the
combination of American ginseng (Panax quinquefolius)a n d
licorice extracts (Glycyrrhiza uralensis) would synergistically
or antagonistically aﬀect the viability of cultured hepato-
carcinoma cell line (Hep-G2). An isobolographic analysis
was utilized to eﬃciently depict synergistic, antagonistic
and additive responses in Hep-G2 cells. Isobolographic
analysis provides a clear graphical view of the interac-
tions between the two components and has been utilized
to depict interactions between two drug combinations
[19].
2. Methods
2.1. Plant Materials. Dried ginseng (Panax quinquefolius)
and licorice (Glycyrrhiza uralensis) roots were purchased
locally (Singapore). Ginsenoside HPLC standards (Rg1, Re,
Rb1, Rc, Rd) were purchased from Chromadex Inc. (Santa
Ana, CA, USA) and glycyrrhizic acid standard was pur-
chased from Sigma (Steinheim, Germany), triﬂuoroacetic
acid (TFA) was obtained from Merck (Whitehouse Station,
NJ, USA). Acetonitrile and methanol were of HPLC grade
(Tedia Inc., Fairﬁeld, OH, USA), ethanol was of analytical
grade (Fisher Scientiﬁc, UK).
Dried ginseng root (Panax quinquefolius)w a sg r o u n d
into a powder and reﬂuxed in methanol (500mL) for 3h,
ﬁltered twice (Whatman no 4) and the extraction was
repeated three times. The solution was concentrated under
vacuum, and the extract was applied to a preconditioned
polymeric absorbent Amberlite XAD-4 (Sigma, St. Louis,
M O ,U S A )c o l u m n( p o r ed i a m e t e ro f4 0˚ A, bed volume of
60cm3, ﬂow rate of 10mL/min) and washed with distilled
water (1L) to remove polar compounds as previously
described [20]. Ginsenosides were eluted from the column
using absolute ethanol (500mL) and concentrated under
vacuum, lyophilized and is herein referred to as the ginseng
extract (GE).
Powdered dried licorice (Glycyrrhiza uralensis)r o o tw a s
reﬂuxed for 2.5h in methanol (70%, 400mL), ﬁltered twice,
extracted three times and concentrated under vacuum and is
herein referred to as the licorice extract (LE).
2.2. HPLC Analysis. AW a t e r sH P L C( M i l f o r d ,M A ,U S A )
equipped with quaternary gradient pump and a photodiode-
array (PDA) detector was used to assess the amount of either
ginsenosides or glycyrrhizic acid in the respective extracts.
The HPLC analysis was conducted using a reverse-phase C18
column (C18, 4.6 × 250mm, 5μm particle size, Waters) with
a column temperature of 25◦C, injection volume of 20μL
and detection wavelength of 203nm for ginsenosides and
254nm for GA. GE, ginsenosides standards, LE and GA were
separately dissolved in methanol, ﬁltered through a 0.45μm
syringe ﬁlter (Minisart, Germany), prior to analysis. HPLC
analysis for GE consisted of two separate gradient programs
(referred to as gradients 1 and 2), due to the similar
retention times of ginsenosides Rg1 and Re. Both solvent
programs consisted of the combination of water (A) and
acetonitrile (B). Gradient program 1 (percentage acetonitrile
and ﬂow rate are enclosed in parenthesis) was as listed:
Time 0 (20% B, 1mL/min), 20min (25% B, 0.7mL/min),
40min (49% B, 0.7mL/min), 50 min (100% B, 0.7mL/min),
and 60 min (80% B, 0.7mL/min). Gradient program 2
consisted of: Time 0 (20% B, 1mL/min), 45 min 22%
B, 0.7mL/min), 50min, (60% B, 0.7mL/min), 60 min
(20% B, 0.7mL/min).
HPLC separation gradient program for LE and GA
utilized 0.5% TFA water (A) and acetonitrile (B) and was as
follows:Time0(20%B),5min(40%B),10–20min(50%B),
and the ﬂow rate was constant at 0.8mL/min. Ginsenoside
Rg1, Re, Rb1, Rc, Rd in the GE and GA in the LE were
identiﬁed according to the respective standard curves and
were assessed in triplicate.
2.3. Cell Culture. Human hepatocarcinoma (Hep-G2) cells
were purchased from American Type Culture Collection
(Manassas, VA, USA). The cells were maintained in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (Sigma), 100U penicillin, and
100μg/mL streptomycin (Gibco, Invitrogen, Canada) in a
humidiﬁed atmosphere of 5% CO2 at 37◦C. Cells were
maintained at a concentration between 2 × 105 and 1 ×
106 cells/mL. Cells were subcultured every 2-3 days by total
medium replacement using 0.25% (w/v) trypsin −0.53mM
EDTAsolution(GIBCO).Viablecellswereassessedby0.04%
trypan blue exclusion dye (MP Biomedicals, Solon, OH,
USA) using a hemocytometer and assessed in quadruplicate.
2.4. Cell Viability MTT Assay. Cell viability was measured by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide, MTT (Sigma) assay, in order to establish an LC50
value (concentration to inhibit 50% of cells). Cells were
seeded at a concentration of 1 × 105 cells/well in a 96-
m i c r o w e l lp l a t ea n dw e r ea l l o w e dt oa d h e r ef o r2 4h .S t o c k
solutions of GE and LE (1.0mg/mL) were dissolved and
ﬁltered through a sterile 0.2μm syringe ﬁlter (Millex GP,
Ireland) before adding to the cells. Extracts were added at
various concentrations (0.2–0.9mg/mL) and incubated for
72h. Controls contained Hep-G2 cells, culture medium,
but no extracts. At the end of 72h, the extract-containing
medium was removed and 100μLo f0 . 5m g / m Lo fM T Tw a s
added and incubated for 4h as previously described [21],
crystals were solubilized in 100μL of 10% SDS (National
University of Medical Institution, Singapore) in 0.01N HCl
and incubated overnight. The absorbance was measured
at 550nm using a microplate reader (Multiskan Spectrum,
Thermo Electron Corporation, Waltham, MA, USA) and
the results were expressed as the percentage of viable cells
with respect to the untreated control cells. Cell viability (%)
was calculated as (mean absorbance of the sample/mean
absorbance of the control) × 100.Evidence-Based Complementary and Alternative Medicine 3
2.5. Isobologram Analysis. The interactions between GE and
LE were analyzed with the use of an isobologram and test of
signiﬁcanceaccordingtothemethodofTallarida(2000)[22].
The LC50 values for ginseng and licorice extracts described
above were used to plot the isobologram. The LC50 value
for GE was plotted on the x-axis, while the LC50 value
for LE on the y-axis. The line connecting the two points
is referred to as the line of additivity and represents the
predicted LC50 (refer to (1)) of diﬀerent combinations of
extracts. Antagonistic combinations are points that lie above
the line, while synergistic combinations are points below
the line [22]. The ﬁxed ratio design was used. Brieﬂy, ﬁve
fractions (1/5, 1/3, 1/2, 2/3, 4/5) of GE to LE were used to
test the interactions of the two extracts (refer to (2)). LC50
values were ﬁrst obtained for GE and LE alone and then the
LC50 values were obtained for each of the ﬁve fractions.
2.6. Cell LDH Activity. Hep-G2 cells were seeded at a
concentration of 5 × 105 cells/mL in 24-well plates and
allowed to adhere for 24h. The medium was removed and
extracts (ginseng, licorice or the ﬁve fractions) at their
respective LC50 concentration were added to the wells. The
concentrations used were 0.64 mg/mL (GE), 0.53mg/mL
(LE), 0.64mg/mL (f1/5), 0.70mg/mL (f1/3), 0.74mg/mL
(f1/2), 0.74mg/mL (f2/3) and 0.69mg/mL (f4/5). Cells were
i n c u b a t e df o r2 4 ,4 8a n d7 2h ,a n du n t r e a t e dc e l l sa c t e da s
control. At the end of each incubation time, the medium was
removed and tested for LDH activity as previously described
[5].
2.7. Cell-Cycle Analysis. GE, LE and ﬁve fractions (1/5,
1/3, 1/2, 2/3, 4/5) were added to Hep-G2 cells at their
respective LC50 concentrations. Cells were incubated for 24,
48 and 72h with untreated cells acting as controls. Cell-
cycle analysis was determined as previously described [21].
Brieﬂy, cells were trypsinized, washed with PBS and the
cellular pellet was ﬁxed in ice-cold 70% ethanol overnight at
4◦C. The supernatant was removed by centrifugation, 1mL
of PBS containing 50μg/mL propidium iodide (Sigma) and
100U/mL RNAse A (Applichem Inc, Cheshire, CT, USA)
were added and incubated at room temperature for 1h
before data acquisition using Dako Cytomation Cyan LX
FlowCytometry(BeckmanCoulter,Fullerton,CA,USA)and
analyzed with Dako Summit v4.3 software package.
2.8. Statistical and Data Analysis. T h eL C 5 0v a l u e so fG E ,
LE and the ﬁve fractions were determined from ﬁve separate
experiments with ﬁve replicates for each experiment. LDH
and cell-cycle analysis were repeated on three separate
occasionswiththreereplicates.Dataareexpressedasmean ±
standarddeviation(SD).Aone-wayANOVAwithTukeypost
hoc comparison of means was used to test for signiﬁcance
(P<. 05) of LDH and cell-cycle analysis using the SPSS
statistical software (v12.0, Chicago, IL, USA).
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Figure 1: The eﬀect of GE and LE on Hep-G2 viability. The results
are expressed as mean ± SD of ﬁve separate experiments with ﬁve
replicates.
GE and LE variables represent the experimentally deter-
mined LC50 values of ginseng and licorice extracts, and
variable f represents the ﬁx ratio fractions (1/5, 1/3, 1/2, 2/3,
4/5) of GE to LE combinations, CAL50 is the theoretical or
calculated LC50.
Determination of Concentrations of Individual Extract in Each
Fraction.
GEf =
fGE
CAL50
,
LEf =

1 − f

LE
CAL50
(2)
Variables f, GE, LE and CAL50 are described above, GEf and
LEf represent the amount each root extract to add to each
fraction.
Additive, Synergy and Antagonism.
Additive: CAL50 −EXPLC50 = 0
Synergy: EXPLC50 < CAL50
Antagonism: EXPLC50 > CAL50
(3)
Variable EXPLC50 is the experimentally derived LC50 of the
fractions and variable CAL50 is described above. The test
of signiﬁcance and the above equations are based on the
reported literature [22, 23].4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: The eﬀect of ﬁve distinct fractions (1/5, 1/3, 1/2, 2/3, 4/5) on Hep-G2 viability (a)–(e). (f) corresponds to the LC50s values of GE,
LE and ﬁve fractions. Bars with diﬀerent letters are signiﬁcantly diﬀerent from each other (P<. 05). Results are expressed as mean ± SD of
ﬁve separate experiments with ﬁve replicates.
3. Results
3.1. HPLC Analysis. Individual ginsenoside analysis showed
thatthepercentageofginsenosidesintheGEwasdetermined
to be Re (20.2 ± 7.8), Rb1 (8.8 ± 0.2), Rg1 (1.5 ± 0.04)
and Rd (0.71 ± 0.01), and the total ginsenosides content
was determined to be 30.9 ± 7.8% (dry weight). Ginsenoside
Rc was detected but the amount was below the limit of
detection. For LE, the total percentage of glycyrrhizic acid
was determined to be 7.1 ± 0.2% (dry weight).
3.2. Dose-Response LC50 Determination of Ginseng and
Licorice Extracts. Figure 1 shows the dose-response relation-
ship of GE and LE. The LC50 was calculated by plotting cell
viability (%) versus log concentration (graph not shown)
which yielded a linear equation of y = −164.32x + 511.58 (r2
= 0.982) for GE and y = −218.84x + 646.88 (r2 = 0.981) for
the LE. The LC50s were determined to be 0.64 ± 0.02mg/mL
for GE and 0.53 ± 0.02mg/mL for LE. Both GE and LE
showed a dose dependent eﬀect on Hep-G2 viability, and the
LE LC50 value was found to be signiﬁcantly (P<. 05) lower
LC50 compared to GE.
3.3. Dose-Response LC50 Determination of Fractions. The
LC50 values of ﬁve fractions corresponding to a ratio of
ginseng to licorice extracts of 1/5, 1/3, 1/2, 2/3 and 4/5 and
are shown in Figures 2(a)–2(e)) and calculated as described
above. Compared to the LC50 of GE, fractions (1/3, 1/2, 2/3,
4/5) were all signiﬁcantly (P<. 05) greater than GE with
the exception of f1/5 which was similar to GE. Furthermore,Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Isobolographic representation of the interaction between
experimentally measured GE, LE and fractions (graphical points)
and the theoretical line of additively (solid line) on Hep-G2 viabil-
ity. The dotted line represents the theoretical standard deviation of
plus/minus 2.5%. Experimental points and error bars are expressed
as mean ± SD of ﬁve separate experiments with ﬁve replicates.
the LC50 for all fractions were signiﬁcantly (P<. 05) greater
when compared to the LC50 of LE (Figure 2(f)).
3.4. Isobolographic Analysis. Figure 3 represents a graphical
view of the eﬀects of the combinations of GE and LE on
Hep-G2 cells viability. An isobologram was created using
the LC50 value for GE, which intersects the x-axis, and the
LC50 value for LE, which intersects the y-axis. The two
points are joined together to form the line of additivity. This
line of additivity refers to the concentrations of GE and LE
extracts needed to produce the same eﬀect if they were to
act alone. Points lying on the line are termed additive, above
the line are antagonistic and below the line are synergistic
[22, 23]. All combinations (1/5, 1/3, 1/2, 2/3 and 4/5) of GE
and LE showed antagonism. They were all greater than the
line of additivity. Fractions 1/2 and 2/3 showed the greatest
antagonistic eﬀect. Table 1 shows the theoretical LC50 and
the experimentally observed LC50. Fractions 1/3 and 1/2
showed the greatest diﬀerence from the theoretical LC50 at
23 and 21%, respectively.
3.5. Cell-Cycle Analysis. Representative DNA histograms of
the various treatments are shown in Figure 4 and corre-
spondinganalysisislistedinTable 2.Apoptoticcells(subG1)
were generally not observed during the cell-cycle analysis.
A majority of fractions tested did not show any signiﬁcant
increase of apoptotic cells at 24h of treatment as compared
to the untreated control. GE signiﬁcantly (P<. 05) increased
sub G1 cells but the increase was only marginal at 48 and
72h. Overall, Hep-G2 cells generally showed a signiﬁcant
(P<. 05) increase in the proportion of cells in the G1 phase
at 24 and 48h time periods with the exception of GE at 24 h.
A decrease in the proportion of G2/M cells was observed for
all extracts and combinations compared to the control. At 48
and 72h of treatment, signiﬁcant reductions (P<. 05) in the
Table 1: Theoretical and observed LC50 values for ginseng and
licorice extracts.
Fractionsa,b
Theoreticalb
LC50 CAL50
(mg/mL)
Observed LC50c
EXPLC50
(mg/mL)
Diﬀerence (%)
f1/5 0.56 0.65 ± 0.01d 16.0
f1/3 0.57 0.70 ± 0.02b,c 22.9
f1/2 0.59 0.75 ± 0.02a,b 21.3
f2/3 0.60 0.74 ± 0.02a 18.1
f4/5 0.62 0.69 ± 0.02c 11.2
aFor example, f1/5 refers to the amount of ginseng (1/5) to licorice (4/5) in
the mixture.
bRefer to the Methods section for a description of the calculations and
variables CAL50 and EXPLC50.
cValues with diﬀerent letters are signiﬁcantly diﬀerent (P<. 05).
proportion of G2/M cells were observed in fractions 1/3, 1/2,
2/3 and 4/5. Cells observed in the S phase were reduced but
not signiﬁcant with the exception of fractions 1/3, 1/2, 2/3
and 4/5 after 24h of treatment.
3.6. LDH Analysis. The eﬀect of diﬀerent treatments and
exposure times on LDH release, a marker of membrane
integrity and damage, is shown in Figure 5.L Et r e a t m e n t
from 24 to 72h did not signiﬁcantly aﬀect the release of LDH
compared to the corresponding control cells. GE treatment
produced the greatest signiﬁcant increase in LDH release,
while fractions that contained a proportion of at least one
half GE (e.g., f1/2, f2/3, f4/5) had signiﬁcant (P<. 05)
increase in LDH release compared to untreated control cells
after 72h of incubation. Fractions 1/2, 2/3 and 4/5 were
found to have a percentage increase of 57% (f1/2), 192%
(f2/3) and 263% (f4/5). GE showed greatest signiﬁcant LDH
increase at all time periods followed by f4/5 at 48h and
fractions f2/3 and f4/5.
4. Discussion
By utilizing an isobolographic analysis, we have eﬀectively
shown that the combinations of ginseng (Panax quinque-
folius) and licorice (Glycyrrhiza uralensis)e x t r a c t sd on o t
produceasynergisticeﬀectonreducingHep-G2cellviability.
On the contrary, the eﬀect was antagonistic. Fractions 1/2
and 2/3 were found to have the highest LC50 values (0.75
± 0.02 and 0.74 ± 0.02 mg/mL, resp.), compared to the
other fractions and fractions 1/3 and 1/2 showed the greatest
percentage diﬀerence when compared to the theoretical or
calculated LC50 (CAL50). Adams et al. [19] also reported
antagonism with the combination G. uralensis with either
Rabdosia rubescens or Scuteellaria baicalensis in equal parts
(1 : 1 fraction) in cultured prostate cancer cells. Glycyrrhiza
uralensis, R. rubescens and S. baicalensis are also found in
TCM prescriptions [24] and PC-SPES formulations [12].
Rabdosia rubescens and S. baicalensis have been reported to
reduce cultured cancer cell viability in a number of cell lines
(Hep-G2, MCF-7, MCF-10A) [25, 26].6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: DNA cell-cycle histograms of Hep-G2 cells. Cells were treated with GE, LE and ﬁve fractions (1/5, 1/3, 1/2, 2/3, 4/5) for 24, 48 and
72h, respectively, at the respective LC50s. Untreated cells acted as controls. Cells were ﬁxed in 70% ethanol and stained with PI as described
in the Methods section. DNA histograms shown are representatives of the assay repeated in three independent experiments with similar
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Table 2: Cell-cycle analysis.
Cell cycle Sub G1 G1 S G2/M
Time (h) 24
Control 0.46 ± 0.27 a 63.19 ± 0.83 a 14.10 ± 0.51 b 20.08 ± 0.83 a
GE 2.05 ± 2.21 a 68.18 ± 5.30 ab 9.39 ± 2.52 ab 19.61 ± 3.39 a
LE 0.79 ± 0.26 a 73.4 ± 2.50 bc 9.54 ± 1.55 ab 15.52 ± 1.76 a
f1/5 0.46 ± 0.05 a 75.01 ± 1.50 bc 9.74 ± 1.87 ab 14.07 ± 2.08 a
f1/3 0.26 ± 0.08 a 76.21 ± 2.01 bc 8.04 ± 1.92 a 14.63 ± 2.50 a
f1/2 0.25 ± 0.03 a 77.34 ± 2.59 c 8.18 ± 2.65 a 13.93 ± 3.01 a
f2/3 0.27 ± 0.01 a 76.86 ± 3.55 bc 8.54 ± 0.47 a 13.76 ± 2.85 a
f4/5 0.31 ± 0.06 a 77.37 ± 4.24 c 7.75 ± 2.42 a 14.12 ± 3.73 a
Time (h) 48
Control 0.40 ± 0.36 a 69.61 ± 0.85 a 10.54 ± 3.09 a 17.74 ± 3.47 b
GE 0.97 ± 0.21 b 77.31 ± 1.76 b 6.86 ± 2.25 a 14.17 ± 1.47 ab
LE 0.67 ± 0.11 ab 78.47 ± 0.65 bc 8.88 ± 1.47 a 11.79 ± 1.63 ab
f1/5 0.32 ± 0.08 a 80.38 ± 0.73 bcd 6.72 ± 2.22 a 12.29 ± 2.86 ab
f1/3 0.31 ± 0.02 a 82.48 ± 1.56 cd 6.27 ± 2.53 a 10.8 ± 1.63 a
f1/2 0.26 ± 0.16 a 82.92 ± 1.76 d 5.76 ± 2.06 a 10.84 ± 2.89 a
f2/3 0.29 ± 0.13 a 83.17 ± 1.77 d 5.08 ± 1.21 a 11.20 ± 0.96 a
f4/5 0.35 ± 0.14 a 82.39 ± 2.11 cd 5.36 ± 1.31 a 11.45 ± 1.19 a
Time (h) 72
Control 0.54 ± 0.12 a 65.76 ± 2.02 a 10.38 ± 4.60 a 20.17 ± 2.14 c
GE 1.14 ± 0.27 c 75.73 ± 0.61 c 6.10 ± 2.87 a 16.15 ± 2.83 bc
LE 1.04 ± 0.11 bc 79.44 ± 0.62 bc 8.71 ± 0.70 a 10.90 ± 0.63 ab
f1/5 0.69 ± 0.23 abc 80.68 ± 0.24 abc 6.80 ± 3.04 a 11.91 ± 2.55 ab
f1/3 0.73 ± 0.16 abc 81.68 ± 0.62 abc 5.95 ± 2.47 a 11.60 ± 2.36 ab
f1/2 0.63 ± 0.02 ab 83.27 ± 1.07 ab 4.77 ± 2.04 a 11.16 ± 1.44 ab
f2/3 0.45 ± 0.12 a 82.93 ± 0.22 a 6.55 ± 2.69 a 9.87 ± 2.12 ab
f4/5 0.42 ± 0.19 a 79.31 ± 1.50 a 7.98 ± 2.74 a 11.82 ± 1.39 ab
Columns of the same category and time period with diﬀerent letters are signiﬁcantly diﬀerent (P<. 05).
In this study, ginseng extract increased the release of
LDH at the LC50 concentration over time with a signiﬁcant
(P<. 05)increaseat48and72hofexposure,whereaslicorice
extract did not. Ginseng extract alone has been shown to be
eﬀective in permeating the cellular membrane of intestinal
cells (Int-407, caco-2 cells) [18] thereby releasing LDH
from the cytoplasm possibly through an interaction with
membrane cholesterol [27]. Notably, when the proportions
of ginseng to licorice contained at least 50% ginseng (f1/2,
f2/3, f4/5) a signiﬁcant (P<. 05) increase in LDH release was
observed at 72h for ginseng and licorice combinations. Both
ginseng and licorice extracts did not produce any substantial
accumulation of sub G1 cells at the LC50 concentration
tested. With the exception of GE at 24h, analysis of the G1
phase of the cell cycle indicated that there was a signiﬁcant
(P<. 05) cell-cycle arrest for all treated cells as compared to
the control at 24 to 72h. In addition, a signiﬁcant (P<. 05)
reduction in cell percentages at the G2/M phase was seen
at 72h. G1 cell-cycle arrest data are in agreement with the
reported literature, licorice extract have been reported to
inhibit cell proliferation, and induce G1 phase arrest in an
estrogen sensitive breast cancer cell line (MCF-7) [28]a n d
aﬀectviabilityinculturedprostatecancercells(LNCaP)[11].
One possible explanation of these antagonistic eﬀects on
cell viability is that the active compounds in ginseng and
licorice extracts may compete for the same cellular receptor.
In the ginseng extract, ginsenoside Re was most abundant
saponin at 20.2% dry weight, followed by ginsenoside
Rb1 (8.8%), Rg1 (1.5%) and Rd (0.7%). Ginsenosides
such as Rg1, a protopanaxatriol type dammarane saponin
that includes structurally related ginsenoside Re, has been
reported to be a functional ligand of the glucocorticoid
receptor [29] and oleanane-type saponins similar to gly-
cyrrhizic acid determined to be 7.1% in the extract have
beencomparedtodexamethasone,asyntheticglucocorticoid
in cell culture experiments [30]. An abundance of active
compounds would saturate a receptor site leading to lower
than expected cellular response than predicted.
Alternatively, licorice under speciﬁc conditions can
exhibit hepato-protection. For example, glycyrrhizin, struc-
turalrelatedtoglycyrrhizicacidhasbeenreportedtoalleviate
intraperitoneal induced liver injury by carbon tetrachloride
(CCl4) in mice by down regulation of pro-inﬂammatory
markers [31]. Pre-treatment of cultured hepatocytes with
licorice or glycyrrhizic acid protected against azathioprine
injury through increasing the intracellular glutathione levels.8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: The eﬀect of GE, LE and ﬁve fractions (1/5, 1/3, 1/2, 2/3,
4/5) on LDH activity. Cells were treated with diﬀerent extracts for
24, 48 and 72h at their respective LC50 concentration determined
from a 72-h MTT assay. Results are expressed as mean ± SD with
three replicates repeated in three separate experiments. Untreated
cells acted as controls. Bars with diﬀerent letters are signiﬁcantly
diﬀerent (P<. 05).
Nakamura et al. reported that glycyrrhizin caused a dose-
dependent inhibition of LDH leakage caused by CCl4 in
primary rat hepatocytes [32]. This protective eﬀect was
evident in this study as fractions that contain more licorice
than ginseng reduced the cytotoxic eﬀect and membrane
permeation of ginseng. Licorice may protect against ginseng
cytotoxicityandthusleadingtotheobservedantagonismand
increase in hepatocyte survival.
Combinations of ginseng to licorice extract using a ﬁx
fraction isobolographic analysis were found to be antago-
nistic rather then synergistic and reduced the cytotoxicity
compared to the individual extracts. Furthermore, licorice
extract was found to reduce ginseng extract membrane per-
meation properties. Further research is needed to determine
the precise cellular trigger and if these observed eﬀects are
cell speciﬁc.
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